A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products

The requirement for visual inspection of pharmaceuticals has been a compendial expectation for over a century, with some advancement of visible particle control strategies in recent years. Current philosophies include a 100% inspection and an Acceptance Sampling Plan inspection. The particles found...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2018-09, Vol.107 (9), p.2306-2309
Main Authors: Spasoff, Andrew, Bennis, Adrian, Atkinson, Susanne, Elliott, Cathal, Freund, Erwin, Narhi, Linda
Format: Article
Language:English
Subjects:
injectable(s)
multiparticulate(s)
particle size
protein aggregation
protein formulation(s)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The requirement for visual inspection of pharmaceuticals has been a compendial expectation for over a century, with some advancement of visible particle control strategies in recent years. Current philosophies include a 100% inspection and an Acceptance Sampling Plan inspection. The particles found during these inspections are normally categorized simply by particle size (visible vs. subvisible), particle source (intrinsic vs. extrinsic) and particle type (inherent vs. extraneous). We believe that a more risk- and science-based approach is attainable, which is grounded in forensic data, toxicological/medical opinions and prior knowledge. We have provided an outline for how to determine patient safety impact of visible particles found in parenteral products and potential actions that could be taken within the quality system regarding lot disposition. We believe this approach focuses efforts on patient safety risks, enhances the use of prior knowledge and improves consistency in how particle observations are handled.
ISSN:0022-3549
1520-6017
DOI:10.1016/j.xphs.2018.05.007